RxDoctor Payments Data

Thach Nguyen, MD

Cardiovascular Disease · Wormleysburg, PANPI 1972504777

Payments from drug & device makers

$624in general payments, 2019–2025

Across 10 payments — averaging $62.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Heartflow, Inc.$164
  • Abiomed$161
  • Cardiovascular Systems Inc.$131
  • Boston Scientific$76
  • Shionogi Inc$28
  • Johnson & Johnson$25
  • plus $38 from 2 others

What the payments were for

  • Travel & lodging$16126%
  • Food & beverage$46374%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$624 in reported general payments places this provider in the 30th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$115,186
Medicare patients
1,273
Services billed
2,133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban281$333,433
XareltoRivaroxaban90$119,184
JardianceEmpagliflozin53$64,853
EntrestoSacubitril/Valsartan57$54,775
Repatha SureclickEvolocumab23$22,868
Metoprolol Succinate574$11,213
FarxigaDapagliflozin Propanediol14$10,321
Atorvastatin Calcium533$7,868
Ezetimibe247$5,847
Losartan Potassium215$3,851
Amiodarone Hcl74$3,738
Diltiazem 24hr Er (Cd)Diltiazem Hcl102$3,220
Ranolazine ErRanolazine30$2,863
Rosuvastatin Calcium149$2,815
ClopidogrelClopidogrel Bisulfate176$2,443

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$25$119,18490 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Wormleysburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →